|
Delaware
|
| |
13-1840497
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification No.) |
|
|
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21 Teaneck, New Jersey (Address of Principal Executive Offices)
|
| |
07666-6712
(Zip Code)
|
|
| Large accelerated filer | | | ☐ | | | | | | Accelerated filer | | | ☒ | |
| Non-accelerated filer | | | ☐ | | | | | | Smaller reporting company | | | ☐ | |
| | |
Page
|
| |||
PART I—FINANCIAL INFORMATION | | | |||||
Item 1.
Financial Statements (unaudited)
|
| | |||||
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 19 | | | |
| | | | 32 | | | |
| | | | 33 | | | |
PART II—OTHER INFORMATION | | | |||||
| | | | 34 | | | |
| | | | 34 | | | |
| | | | 34 | | | |
| | | | 34 | | | |
| | | | 34 | | | |
| | | | 34 | | | |
| | | | 34 | | | |
| | | | 36 | | |
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||
| | |
(unaudited)
(in thousands, except per share amounts) |
| |||||||||||||||||||||
Net sales
|
| | | $ | 191,773 | | | | | $ | 188,688 | | | | | $ | 378,893 | | | | | $ | 376,146 | | |
Cost of goods sold
|
| | | | 129,357 | | | | | | 132,603 | | | | | | 256,317 | | | | | | 259,732 | | |
Gross profit
|
| | | | 62,416 | | | | | | 56,085 | | | | | | 122,576 | | | | | | 116,414 | | |
Selling, general and administrative expenses
|
| | | | 39,795 | | | | | | 36,298 | | | | | | 78,097 | | | | | | 71,522 | | |
Operating income
|
| | | | 22,621 | | | | | | 19,787 | | | | | | 44,479 | | | | | | 44,892 | | |
Interest expense, net
|
| | | | 3,967 | | | | | | 3,515 | | | | | | 7,786 | | | | | | 7,005 | | |
Foreign currency (gains) losses, net
|
| | | | 2,557 | | | | | | (1,018) | | | | | | (2,896) | | | | | | (2,222) | | |
Income before income taxes
|
| | | | 16,097 | | | | | | 17,290 | | | | | | 39,589 | | | | | | 40,109 | | |
Provision (benefit) for income taxes
|
| | | | (14,081) | | | | | | 3,042 | | | | | | (9,342) | | | | | | 6,929 | | |
Net income
|
| | | $ | 30,178 | | | | | $ | 14,248 | | | | | $ | 48,931 | | | | | $ | 33,180 | | |
Net income per share: | | | | | | ||||||||||||||||||||
basic
|
| | | $ | 0.77 | | | | | $ | 0.37 | | | | | $ | 1.25 | | | | | $ | 0.85 | | |
diluted
|
| | | $ | 0.75 | | | | | $ | 0.36 | | | | | $ | 1.22 | | | | | $ | 0.84 | | |
Weighted average common shares outstanding: | | | | | | ||||||||||||||||||||
basic
|
| | | | 39,163 | | | | | | 38,957 | | | | | | 39,128 | | | | | | 38,928 | | |
diluted
|
| | | | 39,978 | | | | | | 39,813 | | | | | | 39,995 | | | | | | 39,690 | | |
Dividends per share
|
| | | $ | 0.10 | | | | | $ | 0.10 | | | | | $ | 0.20 | | | | | $ | 0.20 | | |
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||||||
| | |
(unaudited)
(in thousands) |
| |||||||||||||||||||||||||
Net income
|
| | | $ | 30,178 | | | | | $ | 14,248 | | | | | $ | 48,931 | | | | | $ | 33,180 | | | ||||
Change in fair value of derivative instruments
|
| | | | 1,909 | | | | | | (294) | | | | | | (2,994) | | | | | | (723) | | | ||||
Foreign currency translation adjustment
|
| | | | 2,014 | | | | | | (7,358) | | | | | | (19,715) | | | | | | (17,338) | | | ||||
Unrecognized net pension gains (losses)
|
| | | | 508 | | | | | | 417 | | | | | | 892 | | | | | | 702 | | | ||||
(Provision) benefit for income taxes
|
| | | | (1,371) | | | | | | 1,157 | | | | | | 2,315 | | | | | | 2,706 | | | ||||
Other comprehensive income (loss)
|
| | | | 3,060 | | | | | | (6,078) | | | | | | (19,502) | | | | | | (14,653) | | | ||||
Comprehensive income (loss)
|
| | | $ | 33,238 | | | | | $ | 8,170 | | | | | $ | 29,429 | | | | | $ | 18,527 | | | ||||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| ||||||||
| | |
(unaudited)
(in thousands, except share and per share amounts) |
| |||||||||||
ASSETS | | | | ||||||||||||
Cash and cash equivalents
|
| | | $ | 25,372 | | | | | $ | 29,216 | | | ||
Accounts receivable, net
|
| | | | 114,572 | | | | | | 111,099 | | | ||
Inventories, net
|
| | | | 154,422 | | | | | | 149,786 | | | ||
Other current assets
|
| | | | 15,807 | | | | | | 23,627 | | | ||
Total current assets
|
| | | | 310,173 | | | | | | 313,728 | | | ||
Property, plant and equipment, net
|
| | | | 112,921 | | | | | | 104,414 | | | ||
Intangibles, net
|
| | | | 34,755 | | | | | | 37,281 | | | ||
Other assets
|
| | | | 63,648 | | | | | | 37,895 | | | ||
Total assets
|
| | | $ | 521,497 | | | | | $ | 493,318 | | | ||
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | ||||||||||||
Current portion of long-term debt
|
| | | $ | 2,814 | | | | | $ | 2,809 | | | ||
Accounts payable
|
| | | | 61,226 | | | | | | 63,061 | | | ||
Accrued expenses and other current liabilities
|
| | | | 50,491 | | | | | | 45,463 | | | ||
Total current liabilities
|
| | | | 114,531 | | | | | | 111,333 | | | ||
Revolving credit facility
|
| | | | 20,000 | | | | | | 3,000 | | | ||
Long-term debt
|
| | | | 282,307 | | | | | | 283,709 | | | ||
Other liabilities
|
| | | | 51,351 | | | | | | 65,648 | | | ||
Total liabilities
|
| | | | 468,189 | | | | | | 463,690 | | | ||
Commitments and contingencies (Note 11) | | | | ||||||||||||
Common stock, par value $0.0001; 300,000,000 Class A shares authorized,
18,283,834 and 17,747,793 shares issued and outstanding at December 31, 2015 and June 30, 2015, respectively; 30,000,000 Class B shares authorized, 20,959,811 and 21,320,275 shares issued and outstanding at December 31, 2015 and June 30, 2015, respectively |
| | | | 4 | | | | | | 4 | | | ||
Preferred stock, par value $0.0001; 16,000,000 shares authorized, no shares issued
and outstanding |
| | | | — | | | | | | — | | | ||
Paid-in capital
|
| | | | 116,360 | | | | | | 118,192 | | | ||
Retained earnings (accumulated deficit)
|
| | | | 8,046 | | | | | | (36,968) | | | ||
Accumulated other comprehensive income (loss)
|
| | | | (71,102) | | | | | | (51,600) | | | ||
Total stockholders’ equity
|
| | | | 53,308 | | | | | | 29,628 | | | ||
Total liabilities and stockholders’ equity
|
| | | $ | 521,497 | | | | | $ | 493,318 | | | ||
|
| | |
Six Months
|
| |||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| ||||||||
| | |
(unaudited)
(in thousands) |
| |||||||||||
OPERATING ACTIVITIES | | | | ||||||||||||
Net income
|
| | | $ | 48,931 | | | | | $ | 33,180 | | | ||
Adjustments to reconcile net income to net cash provided (used) by operating activities:
|
| | | | | | | | | | | | | ||
Depreciation and amortization
|
| | | | 10,822 | | | | | | 10,594 | | | ||
Amortization of deferred financing costs and debt discount
|
| | | | 484 | | | | | | 483 | | | ||
Acquisition related accrued compensation
|
| | | | 840 | | | | | | — | | | ||
Acquisition related accrued interest
|
| | | | 689 | | | | | | — | | | ||
Deferred income taxes valuation allowance
|
| | | | (18,787) | | | | | | — | | | ||
Deferred income taxes
|
| | | | (2,828) | | | | | | 176 | | | ||
Foreign currency (gains) losses, net
|
| | | | (2,790) | | | | | | (1,046) | | | ||
Other
|
| | | | 149 | | | | | | (21) | | | ||
Changes in operating assets and liabilities: | | | | ||||||||||||
Accounts receivable, net
|
| | | | (6,885) | | | | | | (3,440) | | | ||
Inventories, net
|
| | | | (12,794) | | | | | | (9,281) | | | ||
Prepaid expenses and other current assets
|
| | | | (309) | | | | | | 4,557 | | | ||
Other assets
|
| | | | (3,343) | | | | | | 101 | | | ||
Accounts payable
|
| | | | (4,842) | | | | | | (1,999) | | | ||
Accrued expenses and other liabilities
|
| | | | (3,733) | | | | | | (7,541) | | | ||
Net cash provided (used) by operating activities
|
| | | | 5,604 | | | | | | 25,763 | | | ||
INVESTING ACTIVITIES | | | | ||||||||||||
Capital expenditures
|
| | | | (17,653) | | | | | | (7,728) | | | ||
Other, net
|
| | | | 263 | | | | | | 809 | | | ||
Net cash provided (used) by investing activities
|
| | | | (17,390) | | | | | | (6,919) | | | ||
FINANCING ACTIVITIES | | | | ||||||||||||
Borrowings under the revolving credit facility
|
| | | | 100,500 | | | | | | — | | | ||
Repayments of the revolving credit facility
|
| | | | (83,500) | | | | | | — | | | ||
Payments of long-term debt, capital leases and other
|
| | | | (2,466) | | | | | | (1,604) | | | ||
Proceeds from common shares issued
|
| | | | 2,078 | | | | | | 158 | | | ||
Dividends paid
|
| | | | (7,827) | | | | | | (7,791) | | | ||
Net cash provided (used) by financing activities
|
| | | | 8,785 | | | | | | (9,237) | | | ||
Effect of exchange rate changes on cash
|
| | | | (843) | | | | | | (739) | | | ||
Net increase (decrease) in cash and cash equivalents
|
| | | | (3,844) | | | | | | 8,868 | | | ||
Cash and cash equivalents at beginning of period
|
| | | | 29,216 | | | | | | 11,821 | | | ||
Cash and cash equivalents at end of period
|
| | | $ | 25,372 | | | | | $ | 20,689 | | | ||
|
For the Periods Ended December 31, 2014
|
| |
Three Months
|
| |
Six Months
|
| ||||||
Consolidated statements of operations
|
| | | | | | | | | | | | |
As reported | | | | ||||||||||
Provision (benefit) for income taxes
|
| | | $ | 1,885 | | | | | $ | 4,223 | | |
Net income (loss)
|
| | | | 15,405 | | | | | | 35,886 | | |
Net income (loss) per share – basic
|
| | | | 0.40 | | | | | | 0.92 | | |
Net income (loss) per share – diluted
|
| | | | 0.39 | | | | | | 0.90 | | |
Correction | | | | ||||||||||
Provision (benefit) for income taxes
|
| | | $ | 1,157 | | | | | $ | 2,706 | | |
Net income (loss)
|
| | | | (1,157) | | | | | | (2,706) | | |
Net income (loss) per share – basic
|
| | | | (0.03) | | | | | | (0.07) | | |
Net income (loss) per share – diluted
|
| | | | (0.03) | | | | | | (0.06) | | |
For the Periods Ended December 31, 2014
|
| |
Three Months
|
| |
Six Months
|
| ||||||
Consolidated statements of operations
|
| | | | | | | | | | | | |
As corrected | | | | ||||||||||
Provision (benefit) for income taxes
|
| | | $ | 3,042 | | | | | $ | 6,929 | | |
Net income (loss)
|
| | | | 14,248 | | | | | | 33,180 | | |
Net income (loss) per share – basic
|
| | | | 0.37 | | | | | | 0.85 | | |
Net income (loss) per share – diluted
|
| | | | 0.36 | | | | | | 0.84 | | |
| As reported | | | | ||||||||||
|
Net income (loss)
|
| | | $ | 15,405 | | | | | $ | 35,886 | | |
|
Other comprehensive income (loss)
|
| | | | (7,235) | | | | | | (17,359) | | |
|
Comprehensive income (loss)
|
| | | | 8,170 | | | | | | 18,527 | | |
| Correction | | | | ||||||||||
|
Net income (loss)
|
| | | $ | (1,157) | | | | | $ | (2,706) | | |
|
Other comprehensive income (loss)
|
| | | | 1,157 | | | | | | 2,706 | | |
|
Comprehensive income (loss)
|
| | | | — | | | | | | — | | |
| As corrected | | | | ||||||||||
|
Net income (loss)
|
| | | $ | 14,248 | | | | | $ | 33,180 | | |
|
Other comprehensive income (loss)
|
| | | | (6,078) | | | | | | (14,653) | | |
|
Comprehensive income (loss)
|
| | | | 8,170 | | | | | | 18,527 | | |
| As reported | | | |||||
|
Net income (loss)
|
| | | $ | 35,886 | | |
|
Deferred income tax
|
| | | | (2,530) | | |
|
Net cash provided (used) by operating activities
|
| | | | 25,763 | | |
| Correction | | | | | | | |
|
Net income (loss)
|
| | | $ | (2,706) | | |
|
Deferred income tax
|
| | | | 2,706 | | |
|
Net cash provided (used) by operating activities
|
| | | | — | | |
| As corrected | | | | | | | |
|
Net income (loss)
|
| | | $ | 33,180 | | |
|
Deferred income tax
|
| | | | 176 | | |
|
Net cash provided (used) by operating activities
|
| | | | 25,763 | | |
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||
Net income
|
| | | $ | 30,178 | | | | | $ | 14,248 | | | | | $ | 48,931 | | | | | $ | 33,180 | | |
Weighted average number of shares – basic
|
| | | | 39,163 | | | | | | 38,957 | | | | | | 39,128 | | | | | | 38,928 | | |
Dilutive effect of stock options and warrant
|
| | | | 815 | | | | | | 856 | | | | | | 867 | | | | | | 762 | | |
Weighted average number of shares – diluted
|
| | | | 39,978 | | | | | | 39,813 | | | | | | 39,995 | | | | | | 39,690 | | |
Net income per share: | | | | | | | | | | | | | | | | | | | | | | | | | |
basic
|
| | | $ | 0.77 | | | | | $ | 0.37 | | | | | $ | 1.25 | | | | | $ | 0.85 | | |
diluted
|
| | | $ | 0.75 | | | | | $ | 0.36 | | | | | $ | 1.22 | | | | | $ | 0.84 | | |
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||||||
Interest expense, net | | | | | | ||||||||||||||||||||||||
Term B Loan
|
| | | $ | 2,927 | | | | | $ | 2,957 | | | | | $ | 5,862 | | | | | $ | 5,921 | | | ||||
Revolving credit facility
|
| | | | 342 | | | | | | 236 | | | | | | 602 | | | | | | 469 | | | ||||
Acquisition related accrued interest
|
| | | | 344 | | | | | | — | | | | | | 689 | | | | | | — | | | ||||
Amortization of deferred financing fees and debt
discount |
| | | | 242 | | | | | | 242 | | | | | | 484 | | | | | | 484 | | | ||||
Other
|
| | | | 169 | | | | | | 115 | | | | | | 255 | | | | | | 228 | | | ||||
Interest expense
|
| | | | 4,024 | | | | | | 3,550 | | | | | | 7,892 | | | | | | 7,102 | | | ||||
Interest (income)
|
| | | | (57) | | | | | | (35) | | | | | | (106) | | | | | | (97) | | | ||||
| | | | $ | 3,967 | | | | | $ | 3,515 | | | | | $ | 7,786 | | | | | $ | 7,005 | | | ||||
Depreciation and amortization | | | | | | ||||||||||||||||||||||||
Depreciation of property, plant and equipment
|
| | | $ | 4,075 | | | | | $ | 4,123 | | | | | $ | 8,186 | | | | | $ | 8,351 | | | ||||
Amortization of intangible assets
|
| | | | 1,260 | | | | | | 1,057 | | | | | | 2,519 | | | | | | 2,126 | | | ||||
Amortization of other assets
|
| | | | 58 | | | | | | 61 | | | | | | 117 | | | | | | 117 | | | ||||
| | | | $ | 5,393 | | | | | $ | 5,241 | | | | | $ | 10,822 | | | | | $ | 10,594 | | | ||||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| ||||||||
Inventories | | | | | | | | | | | | | | ||
Raw materials
|
| | | $ | 45,378 | | | | | $ | 40,012 | | | ||
Work-in-process
|
| | | | 8,987 | | | | | | 7,617 | | | ||
Finished goods
|
| | | | 100,057 | | | | | | 102,157 | | | ||
| | | | $ | 154,422 | | | | | $ | 149,786 | | | ||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| ||||||||
Accrued expenses and other current liabilities | | | | | | | | | | | | | | ||
Employee related
|
| | | $ | 16,858 | | | | | $ | 22,273 | | | ||
Commissions and rebates
|
| | | | 4,448 | | | | | | 4,148 | | | ||
Insurance related
|
| | | | 1,685 | | | | | | 1,368 | | | ||
Professional fees
|
| | | | 3,987 | | | | | | 3,543 | | | ||
Income and other taxes
|
| | | | 4,074 | | | | | | 817 | | | ||
Deferred consideration on acquisitions
|
| | | | 1,250 | | | | | | 1,196 | | | ||
Fair value of derivatives
|
| | | | 4,536 | | | | | | 1,542 | | | ||
Other
|
| | | | 13,653 | | | | | | 10,576 | | | ||
| | | | $ | 50,491 | | | | | $ | 45,463 | | | ||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| ||||||||
Accumulated other comprehensive income (loss) | | | | | | | | | | | | | | ||
Derivative instruments
|
| | | $ | (4,536) | | | | | $ | (1,542) | | | ||
Foreign currency translation adjustment
|
| | | | (52,438) | | | | | | (32,723) | | | ||
Unrecognized net pension gains (losses)
|
| | | | (18,992) | | | | | | (19,884) | | | ||
(Provision) benefit for income taxes on derivative instruments
|
| | | | (670) | | | | | | 63 | | | ||
(Provision) benefit for incomes taxes on long-term intercompany
investments |
| | | | 8,166 | | | | | | 4,923 | | | ||
(Provision) benefit for income taxes on pension gains (losses)
|
| | | | (2,632) | | | | | | (2,437) | | | ||
| | | | $ | (71,102) | | | | | $ | (51,600) | | | ||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| ||||||||
Term B loan due April 2021
|
| | | $ | 285,650 | | | | | $ | 287,100 | | | ||
Capitalized lease obligations
|
| | | | 19 | | | | | | 18 | | | ||
| | | | | 285,669 | | | | | | 287,118 | | | ||
Unamortized debt discount
|
| | | | (548) | | | | | | (600) | | | ||
| | | | | 285,121 | | | | | | 286,518 | | | ||
Less: current maturities
|
| | | | (2,814) | | | | | | (2,809) | | | ||
| | | | $ | 282,307 | | | | | $ | 283,709 | | | ||
|
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||||||
Service cost – benefits earned during the period
|
| | | $ | 751 | | | | | $ | 656 | | | | | $ | 1,470 | | | | | $ | 1,477 | | | ||||
Interest cost on benefit obligation
|
| | | | 757 | | | | | | 574 | | | | | | 1,446 | | | | | | 1,309 | | | ||||
Expected return on plan assets
|
| | | | (846) | | | | | | (648) | | | | | | (1,588) | | | | | | (1,414) | | | ||||
Amortization of net actuarial (gain) loss and prior
service costs |
| | | | 508 | | | | | | 417 | | | | | | 892 | | | | | | 702 | | | ||||
Net periodic pension expense
|
| | | $ | 1,170 | | | | | $ | 999 | | | | | $ | 2,220 | | | | | $ | 2,074 | | | ||||
|
| | | | | |
Notional
Amount at December 31, 2015 |
| |
Fair value as of
|
| |||||||||
Instrument
|
| |
Hedge
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| |||||||||
Options
|
| |
Brazilian Real calls
|
| |
R$156,000
|
| | | $ | 675 | | | | | $ | 493 | | |
Options
|
| |
Brazilian Real puts
|
| |
R$156,000
|
| | | $ | (5,211) | | | | | $ | (2,035) | | |
As of
|
| |
December 31, 2015
|
| |
June 30, 2015
|
| ||||||||||||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| ||||||||||||||||||
Derivatives
|
| | | $ | — | | | | | $ | (4,536) | | | | | $ | — | | | | | $ | — | | | | | $ | (1,542) | | | | | $ | — | | |
Deferred consideration on acquisitions
|
| | | $ | — | | | | | $ | — | | | | | $ | 5,958 | | | | | $ | — | | | | | $ | — | | | | | $ | 5,465 | | |
|
Balance, June 30, 2015
|
| | | $ | 5,465 | | | |
|
Acquisition related accrued interest
|
| | | | 689 | | | |
|
Payment and other
|
| | | | (196) | | | |
|
Balance, December 31, 2015
|
| | | $ | 5,958 | | | |
|
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||||||
Net sales | | | | | | ||||||||||||||||||||||||
Animal Health
|
| | | $ | 121,504 | | | | | $ | 118,785 | | | | | $ | 241,638 | | | | | $ | 236,010 | | | ||||
Mineral Nutrition
|
| | | | 58,853 | | | | | | 58,742 | | | | | | 113,322 | | | | | | 114,189 | | | ||||
Performance Products
|
| | | | 11,416 | | | | | | 11,161 | | | | | | 23,933 | | | | | | 25,947 | | | ||||
| | | | $ | 191,773 | | | | | $ | 188,688 | | | | | $ | 378,893 | | | | | $ | 376,146 | | | ||||
Depreciation and amortization | | | | | | ||||||||||||||||||||||||
Animal Health
|
| | | $ | 3,829 | | | | | $ | 3,710 | | | | | $ | 7,705 | | | | | $ | 7,538 | | | ||||
Mineral Nutrition
|
| | | | 612 | | | | | | 605 | | | | | | 1,220 | | | | | | 1,209 | | | ||||
Performance Products
|
| | | | 194 | | | | | | 147 | | | | | | 388 | | | | | | 293 | | | ||||
Corporate
|
| | | | 758 | | | | | | 779 | | | | | | 1,509 | | | | | | 1,554 | | | ||||
| | | | $ | 5,393 | | | | | $ | 5,241 | | | | | $ | 10,822 | | | | | $ | 10,594 | | | ||||
|
| | |
Three Months
|
| |
Six Months
|
|||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
|||||||||||||||
Adjusted EBITDA | | | | | | ||||||||||||||||||||||
Animal Health
|
| | | $ | 32,351 | | | | | $ | 28,296 | | | | | $ | 63,827 | | | | | $ | 60,750 | ||||
Mineral Nutrition
|
| | | | 4,189 | | | | | | 3,754 | | | | | | 7,349 | | | | | | 7,233 | ||||
Performance Products
|
| | | | (8) | | | | | | 162 | | | | | | 78 | | | | | | 1,198 | ||||
Corporate
|
| | | | (8,098) | | | | | | (7,184) | | | | | | (15,113) | | | | | | (13,695) | ||||
| | | | $ | 28,434 | | | | | $ | 25,028 | | | | | $ | 56,141 | | | | | $ | 55,486 | ||||
Reconciliation of Adjusted EBITDA to income before income taxes
|
| | | | | ||||||||||||||||||||||
Adjusted EBITDA
|
| | | $ | 28,434 | | | | | $ | 25,028 | | | | | $ | 56,141 | | | | | $ | 55,486 | ||||
Depreciation and amortization
|
| | | | (5,393) | | | | | | (5,241) | | | | | | (10,822) | | | | | | (10,594) | ||||
Acquisition related accrued compensation
|
| | | | (420) | | | | | | — | | | | | | (840) | | | | | | — | ||||
Interest expense, net
|
| | | | (3,967) | | | | | | (3,515) | | | | | | (7,786) | | | | | | (7,005) | ||||
Foreign currency gains (losses), net
|
| | | | (2,557) | | | | | | 1,018 | | | | | | 2,896 | | | | | | 2,222 | ||||
Income before income taxes
|
| | | $ | 16,097 | | | | | $ | 17,290 | | | | | $ | 39,589 | | | | | $ | 40,109 | ||||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| ||||||||
Identifiable assets | | | | | | | | | | | | | | ||
Animal Health
|
| | | $ | 370,522 | | | | | $ | 361,078 | | | ||
Mineral Nutrition
|
| | | | 62,771 | | | | | | 59,881 | | | ||
Performance Products
|
| | | | 23,718 | | | | | | 22,255 | | | ||
Corporate
|
| | | | 64,486 | | | | | | 50,104 | | | ||
| | | | $ | 521,497 | | | | | $ | 493,318 | | | ||
|
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
Change
|
| |
2015
|
| |
2014
|
| |
Change
|
| ||||||||||||||||||||||||||||||
| | |
(in thousands, except per share)
|
| |
(in thousands, except per share)
|
| ||||||||||||||||||||||||||||||||||||||||||
Net sales
|
| | | $ | 191,773 | | | | | $ | 188,688 | | | | | $ | 3,085 | | | | |
|
2%
|
| | | | $ | 378,893 | | | | | $ | 376,146 | | | | | $ | 2,747 | | | | |
|
1%
|
| |
Gross profit
|
| | | | 62,416 | | | | | | 56,085 | | | | | | 6,331 | | | | |
|
11%
|
| | | | | 122,576 | | | | | | 116,414 | | | | | | 6,162 | | | | |
|
5%
|
| |
Selling, general and administrative expenses
|
| | | | 39,795 | | | | | | 36,298 | | | | | | 3,497 | | | | |
|
10%
|
| | | | | 78,097 | | | | | | 71,522 | | | | | | 6,575 | | | | |
|
9%
|
| |
Operating income
|
| | | | 22,621 | | | | | | 19,787 | | | | | | 2,834 | | | | |
|
14%
|
| | | | | 44,479 | | | | | | 44,892 | | | | | | (413) | | | | |
|
(1)%
|
| |
Interest expense, net
|
| | | | 3,967 | | | | | | 3,515 | | | | | | 452 | | | | |
|
13%
|
| | | | | 7,786 | | | | | | 7,005 | | | | | | 781 | | | | |
|
11%
|
| |
Foreign currency (gains) losses, net
|
| | | | 2,557 | | | | | | (1,018) | | | | | | 3,575 | | | | |
|
*
|
| | | | | (2,896) | | | | | | (2,222) | | | | | | (674) | | | | |
|
*
|
| |
Income before income taxes
|
| | | | 16,097 | | | | | | 17,290 | | | | | | (1,193) | | | | |
|
(7)%
|
| | | | | 39,589 | | | | | | 40,109 | | | | | | (520) | | | | |
|
(1)%
|
| |
Provision (benefit) for income taxes
|
| | | | (14,081) | | | | | | 3,042 | | | | | | (17,123) | | | | |
|
*
|
| | | | | (9,342) | | | | | | 6,929 | | | | | | (16,271) | | | | |
|
*
|
| |
Net income
|
| | | $ | 30,178 | | | | | $ | 14,248 | | | | | $ | 15,930 | | | | |
|
112%
|
| | | | $ | 48,931 | | | | | $ | 33,180 | | | | | $ | 15,751 | | | | |
|
47%
|
| |
Net income per share | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
basic
|
| | | $ | 0.77 | | | | | $ | 0.37 | | | | | $ | 0.40 | | | | | | | | | | | $ | 1.25 | | | | | $ | 0.85 | | | | | $ | 0.40 | | | | | | | | |
diluted
|
| | | $ | 0.75 | | | | | $ | 0.36 | | | | | $ | 0.39 | | | | | | | | | | | $ | 1.22 | | | | | $ | 0.84 | | | | | $ | 0.38 | | | | | | | | |
Weighted average number of shares outstanding
|
| | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
basic
|
| | | | 39,163 | | | | | | 38,957 | | | | | | | | | | | | | | | | | | 39,128 | | | | | | 38,928 | | | | | ||||||||||
diluted
|
| | | | 39,978 | | | | | | 39,813 | | | | | | | | | | | | | | | | | | 39,995 | | | | | | 39,690 | | | | | ||||||||||
Ratio to net sales | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Gross profit
|
| | | | 32.5% | | | | | | 29.7% | | | | | | | | | | | | | | | | | | 32.4% | | | | | | 30.9% | | | | | ||||||||||
Selling, general and administrative expenses
|
| | | | 20.8% | | | | | | 19.2% | | | | | | | | | | | | | | | | | | 20.6% | | | | | | 19.0% | | | | | ||||||||||
Operating income
|
| | | | 11.8% | | | | | | 10.5% | | | | | | | | | | | | | | | | | | 11.7% | | | | | | 11.9% | | | | | ||||||||||
Income before income taxes
|
| | | | 8.4% | | | | | | 9.2% | | | | | | | | | | | | | | | | | | 10.4% | | | | | | 10.7% | | | | | ||||||||||
Net income
|
| | | | 15.7% | | | | | | 7.6% | | | | | | | | | | | | | | | | | | 12.9% | | | | | | 8.8% | | | | | ||||||||||
Effective tax rate
|
| | | | (87.5)% | | | | | | 17.6% | | | | | | | | | | | | | | | | | | (23.6)% | | | | | | 17.3% | | | | |
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
Change
|
| |
2015
|
| |
2014
|
| |
Change
|
| ||||||||||||||||||||||||||||||
| | |
(in thousands)
|
| |
(in thousands)
|
| ||||||||||||||||||||||||||||||||||||||||||
Net Sales | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
MFAs and other
|
| | | $ | 85,569 | | | | | $ | 87,393 | | | | | $ | (1,824) | | | | |
|
(2)%
|
| | | | $ | 171,090 | | | | | $ | 168,175 | | | | | $ | 2,915 | | | | |
|
2%
|
| |
Nutritional specialties
|
| | | | 24,222 | | | | | | 20,786 | | | | | | 3,436 | | | | |
|
17%
|
| | | | | 46,592 | | | | | | 40,303 | | | | | | 6,289 | | | | |
|
16%
|
| |
Vaccines
|
| | | | 11,713 | | | | | | 10,606 | | | | | | 1,107 | | | | |
|
10%
|
| | | | | 23,956 | | | | | | 27,532 | | | | | | (3,576) | | | | |
|
(13)%
|
| |
Animal Health
|
| | | | 121,504 | | | | | | 118,785 | | | | | | 2,719 | | | | |
|
2%
|
| | | | | 241,638 | | | | | | 236,010 | | | | | | 5,628 | | | | |
|
2%
|
| |
Mineral Nutrition
|
| | | | 58,853 | | | | | | 58,742 | | | | | | 111 | | | | |
|
0%
|
| | | | | 113,322 | | | | | | 114,189 | | | | | | (867) | | | | |
|
(1)%
|
| |
Performance Products
|
| | | | 11,416 | | | | | | 11,161 | | | | | | 255 | | | | |
|
2%
|
| | | | | 23,933 | | | | | | 25,947 | | | | | | (2,014) | | | | |
|
(8)%
|
| |
Total
|
| | | $ | 191,773 | | | | | $ | 188,688 | | | | | $ | 3,085 | | | | |
|
2%
|
| | | | $ | 378,893 | | | | | $ | 376,146 | | | | | $ | 2,747 | | | | |
|
1%
|
| |
Adjusted EBITDA | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Animal Health
|
| | | $ | 32,351 | | | | | $ | 28,296 | | | | | $ | 4,055 | | | | |
|
14%
|
| | | | $ | 63,827 | | | | | $ | 60,750 | | | | | $ | 3,077 | | | | |
|
5%
|
| |
Mineral Nutrition
|
| | | | 4,189 | | | | | | 3,754 | | | | | | 435 | | | | |
|
12%
|
| | | | | 7,349 | | | | | | 7,233 | | | | | | 116 | | | | |
|
2%
|
| |
Performance Products
|
| | | | (8) | | | | | | 162 | | | | | | (170) | | | | |
|
*
|
| | | | | 78 | | | | | | 1,198 | | | | | | (1,120) | | | | |
|
(93)%
|
| |
Corporate
|
| | | | (8,098) | | | | | | (7,184) | | | | | | (914) | | | | |
|
*
|
| | | | | (15,113) | | | | | | (13,695) | | | | | | (1,418) | | | | |
|
*
|
| |
Total
|
| | | $ | 28,434 | | | | | $ | 25,028 | | | | | $ | 3,406 | | | | |
|
14%
|
| | | | $ | 56,141 | | | | | $ | 55,486 | | | | | $ | 655 | | | | |
|
1%
|
| |
Adjusted EBITDA ratio to segment net
sales |
| | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Animal Health
|
| | | | 26.6% | | | | | | 23.8% | | | | | | | | | | | | | | | | | | 26.4% | | | | | | 25.7% | | | | | | | | | | | | | | |
Mineral Nutrition
|
| | | | 7.1% | | | | | | 6.4% | | | | | | | | | | | | | | | | | | 6.5% | | | | | | 6.3% | | | | | | | | | | | | | | |
Performance Products
|
| | | | (0.1)% | | | | | | 1.5% | | | | | | | | | | | | | | | | | | 0.3% | | | | | | 4.6% | | | | | | | | | | |||||
Corporate(1)
|
| | | | (4.2)% | | | | | | (3.8)% | | | | | | | | | | | | | | | | | | (4.0)% | | | | | | (3.6)% | | | | | | | | | | | | | | |
Total(1)
|
| | | | 14.8% | | | | | | 13.3% | | | | | | | | | | | | | | | | | | 14.8% | | | | | | 14.8% | | | | | | | | | | | | | | |
| | |
Three Months
|
| |
Six Months
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
Change
|
| |
2015
|
| |
2014
|
| |
Change
|
| ||||||||||||||||||||||||||||||||||||||
| | |
(in thousands)
|
| |
(in thousands)
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Net income
|
| | | $ | 30,178 | | | | | $ | 14,248 | | | | | $ | 15,930 | | | | |
|
112%
|
| | | | $ | 48,931 | | | | | $ | 33,180 | | | | | $ | 15,751 | | | | |
|
47%
|
| | ||||||||
Interest expense, net
|
| | | | 3,967 | | | | | | 3,515 | | | | | | 452 | | | | |
|
13%
|
| | | | | 7,786 | | | | | | 7,005 | | | | | | 781 | | | | |
|
11%
|
| | ||||||||
Provision (benefit) for income
taxes |
| | | | (14,081) | | | | | | 3,042 | | | | | | (17,123) | | | | |
|
*
|
| | | | | (9,342) | | | | | | 6,929 | | | | | | (16,271) | | | | |
|
*
|
| | ||||||||
Depreciation and amortization
|
| | | | 5,393 | | | | | | 5,241 | | | | | | 152 | | | | |
|
3%
|
| | | | | 10,822 | | | | | | 10,594 | | | | | | 228 | | | | |
|
2%
|
| | ||||||||
EBITDA
|
| | | | 25,457 | | | | | | 26,046 | | | | | | (589) | | | | |
|
(2)%
|
| | | | | 58,197 | | | | | | 57,708 | | | | | | 489 | | | | |
|
1%
|
| | ||||||||
Acquisition related accrued compensation
|
| | | | 420 | | | | | | — | | | | | | 420 | | | | |
|
*
|
| | | | | 840 | | | | | | — | | | | | | 840 | | | | |
|
*
|
| | ||||||||
Foreign currency (gains) losses,
net |
| | | | 2,557 | | | | | | (1,018) | | | | | | 3,575 | | | | |
|
*
|
| | | | | (2,896) | | | | | | (2,222) | | | | | | (674) | | | | |
|
*
|
| | ||||||||
Adjusted EBITDA
|
| | | $ | 28,434 | | | | | $ | 25,028 | | | | | $ | 3,406 | | | | |
|
14%
|
| | | | $ | 56,141 | | | | | $ | 55,486 | | | | | $ | 655 | | | | |
|
1%
|
| | ||||||||
|
| | |
Three Months
|
| |||||||||||||||||||||||||||||||||
| | |
As Reported
|
| |
Adjustments
|
| |
Adjusted
|
| |||||||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||||||||
| | |
(in thousands, except per share amounts)
|
| |||||||||||||||||||||||||||||||||
Selling, general and administrative expenses(1)
|
| | | $ | 39,795 | | | | | $ | 36,298 | | | | | $ | (1,680) | | | | | $ | (1,057) | | | | | $ | 38,115 | | | | | $ | 35,241 | | |
Operating income
|
| | | | 22,621 | | | | | | 19,787 | | | | | | 1,680 | | | | | | 1,057 | | | | | | 24,301 | | | | | | 20,844 | | |
Interest expense, net(2)
|
| | | | 3,967 | | | | | | 3,515 | | | | | | (344) | | | | | | — | | | | | | 3,623 | | | | | | 3,515 | | |
Foreign currency (gains) losses, net
|
| | | | 2,557 | | | | | | (1,018) | | | | | | (2,557) | | | | | | 1,018 | | | | | | — | | | | | | — | | |
Income before income taxes
|
| | | | 16,097 | | | | | | 17,290 | | | | | | 4,581 | | | | | | 39 | | | | | | 20,678 | | | | | | 17,329 | | |
Provision (benefit) for income taxes(3)
|
| | | | (14,081) | | | | | | 3,042 | | | | | | 19,280 | | | | | | 178 | | | | | | 5,199 | | | | | | 3,220 | | |
Net income (loss)
|
| | | $ | 30,178 | | | | | $ | 14,248 | | | | | $ | (14,699) | | | | | $ | (139) | | | | | $ | 15,479 | | | | | $ | 14,109 | | |
Net income per share | | | | | | | | ||||||||||||||||||||||||||||||
basic
|
| | | $ | 0.77 | | | | | $ | 0.37 | | | | | $ | (0.37) | | | | | $ | (0.01) | | | | | $ | 0.40 | | | | | $ | 0.36 | | |
diluted
|
| | | $ | 0.75 | | | | | $ | 0.36 | | | | | $ | (0.36) | | | | | $ | (0.01) | | | | | $ | 0.39 | | | | | $ | 0.35 | | |
Weighted average common shares outstanding
|
| | | | | | | ||||||||||||||||||||||||||||||
basic
|
| | | | 39,163 | | | | | | 38,957 | | | | | | | | | | | | | | | | | | 39,163 | | | | | | 38,957 | | |
diluted
|
| | | | 39,978 | | | | | | 39,813 | | | | | | | | | | | | | | | | | | 39,978 | | | | | | 39,813 | | |
Ratio to net sales | | | | | | | | ||||||||||||||||||||||||||||||
Gross profit
|
| | | | 32.5% | | | | | | 29.7% | | | | | | | | | | | | | | | | | | 32.5% | | | | | | 29.7% | | |
Selling, general and administrative expenses
|
| | | | 20.8% | | | | | | 19.2% | | | | | | | | | | | | | | | | | | 19.9% | | | | | | 18.7% | | |
Operating income
|
| | | | 11.8% | | | | | | 10.5% | | | | | | | | | | | | | | | | | | 12.7% | | | | | | 11.0% | | |
Income before income taxes
|
| | | | 8.4% | | | | | | 9.2% | | | | | | | | | | | | | | | | | | 10.8% | | | | | | 9.2% | | |
Net income
|
| | | | 15.7% | | | | | | 7.6% | | | | | | | | | | | | | | | | | | 8.1% | | | | | | 7.5% | | |
Effective tax rate
|
| | | | (87.5)% | | | | | | 17.6% | | | | | | | | | | | | | | | | | | 25.1% | | | | | | 18.6% | | |
| | |
Six Months
|
| |||||||||||||||||||||||||||||||||
| | |
As Reported
|
| |
Adjustments
|
| |
Adjusted
|
| |||||||||||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| |
2015
|
| |
2014
|
| ||||||||||||||||||
| | |
(in thousands, except per share amounts)
|
| |||||||||||||||||||||||||||||||||
Selling, general and administrative expenses(4)
|
| | | $ | 78,097 | | | | | $ | 71,522 | | | | | $ | (3,359) | | | | | $ | (2,126) | | | | | $ | 74,738 | | | | | $ | 69,396 | | |
Operating income
|
| | | | 44,479 | | | | | | 44,892 | | | | | | 3,359 | | | | | | 2,126 | | | | | | 47,838 | | | | | | 47,018 | | |
Interest expense, net(5)
|
| | | | 7,786 | | | | | | 7,005 | | | | | | (689) | | | | | | — | | | | | | 7,097 | | | | | | 7,005 | | |
Foreign currency (gains) losses, net
|
| | | | (2,896) | | | | | | (2,222) | | | | | | 2,896 | | | | | | 2,222 | | | | | | — | | | | | | — | | |
Income before income taxes
|
| | | | 39,589 | | | | | | 40,109 | | | | | | 1,152 | | | | | | (96) | | | | | | 40,741 | | | | | | 40,013 | | |
Provision (benefit) for income taxes(3)
|
| | | | (9,342) | | | | | | 6,929 | | | | | | 16,856 | | | | | | (1,266) | | | | | | 7,514 | | | | | | 5,663 | | |
Net income (loss)
|
| | | $ | 48,931 | | | | | $ | 33,180 | | | | | $ | (15,704) | | | | | $ | 1,170 | | | | | $ | 33,227 | | | | | $ | 34,350 | | |
Net income per share | | | | | | | | ||||||||||||||||||||||||||||||
basic
|
| | | $ | 1.25 | | | | | $ | 0.85 | | | | | $ | (0.40) | | | | | $ | 0.03 | | | | | $ | 0.85 | | | | | $ | 0.88 | | |
diluted
|
| | | $ | 1.22 | | | | | $ | 0.84 | | | | | $ | (0.39) | | | | | $ | 0.03 | | | | | $ | 0.83 | | | | | $ | 0.87 | | |
Weighted average common shares outstanding
|
| | | | | | | ||||||||||||||||||||||||||||||
basic
|
| | | | 39,128 | | | | | | 38,928 | | | | | | | | | | | | | | | | | | 39,128 | | | | | | 38,928 | | |
diluted
|
| | | | 39,995 | | | | | | 39,690 | | | | | | | | | | | | | | | | | | 39,995 | | | | | | 39,690 | | |
Ratio to net sales | | | | | | | | ||||||||||||||||||||||||||||||
Gross profit
|
| | | | 32.4% | | | | | | 30.9% | | | | | | | | | | | | | | | | | | 32.4% | | | | | | 30.9% | | |
Selling, general and administrative expenses
|
| | | | 20.6% | | | | | | 19.0% | | | | | | | | | | | | | | | | | | 19.7% | | | | | | 18.4% | | |
Operating income
|
| | | | 11.7% | | | | | | 11.9% | | | | | | | | | | | | | | | | | | 12.6% | | | | | | 12.5% | | |
Income before income taxes
|
| | | | 10.4% | | | | | | 10.7% | | | | | | | | | | | | | | | | | | 10.8% | | | | | | 10.6% | | |
Net income
|
| | | | 12.9% | | | | | | 8.8% | | | | | | | | | | | | | | | | | | 8.8% | | | | | | 9.1% | | |
Effective tax rate
|
| | | | (23.6)% | | | | | | 17.3% | | | | | | | | | | | | | | | | | | 18.4% | | | | | | 14.2% | | |
| | |
Six Months
|
| ||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
Change
|
| ||||||||||||
| | |
(in thousands)
|
| ||||||||||||||||||
Cash provided by/(used in): | | | | | ||||||||||||||||||
Operating activities
|
| | | $ | 5,604 | | | | | $ | 25,763 | | | | | $ | (20,159) | | | |||
Investing activities
|
| | | | (17,390) | | | | | | (6,919) | | | | | | (10,471) | | | |||
Financing activities
|
| | | | 8,785 | | | | | | (9,237) | | | | | | 18,022 | | | |||
Effect of exchange-rate changes on cash and cash equivalents
|
| | | | (843) | | | | | | (739) | | | | | | (104) | | | |||
Net increase/(decrease) in cash and cash equivalents
|
| | | $ | (3,844) | | | | | $ | 8,868 | | | | | $ | (12,712) | | | |||
|
| | |
Six Months
|
| ||||||||||||||||||
For the Periods Ended December 31
|
| |
2015
|
| |
2014
|
| |
Change
|
| ||||||||||||
| | |
(in thousands)
|
| ||||||||||||||||||
Adjusted EBITDA
|
| | | $ | 56,141 | | | | | $ | 55,486 | | | | | $ | 655 | | | |||
Interest paid
|
| | | | (6,687) | | | | | | (6,565) | | | | | | (122) | | | |||
Income taxes paid
|
| | | | (7,514) | | | | | | (5,663) | | | | | | (1,851) | | | |||
Changes in operating assets and liabilities and other items
|
| | | | (36,336) | | | | | | (17,495) | | | | | | (18,841) | | | |||
Net cash provided (used) by operating activities
|
| | | $ | 5,604 | | | | | $ | 25,763 | | | | | $ | (20,159) | | | |||
|
As of
|
| |
December 31,
2015 |
| |
June 30,
2015 |
| |
Change
|
| |||||||||
| | |
(in thousands)
|
| |||||||||||||||
Cash and cash equivalents
|
| | | $ | 25,372 | | | | | $ | 29,216 | | | | | $ | (3,844) | | |
Working capital
|
| | | $ | 173,084 | | | | | $ | 175,988 | | | | | $ | (2,904) | | |
Ratio of current assets to current liabilities
|
| | | | 2.55:1 | | | | | | 2.62:1 | | | | | | | | |
| | | | Phibro Animal Health Corporation | | |||
| February 9, 2016 | | | By: | | |
/s/ Jack C. Bendheim
Jack C. Bendheim
President and Chief Executive Officer |
|
| February 9, 2016 | | | By: | | |
/s/ Richard G. Johnson
Richard G. Johnson
Chief Financial Officer |
|
| Dated: February 9, 2016 | | |
/s/ Jack C. Bendheim
Jack C. Bendheim
Chairman, President and Chief Executive Officer |
|
| Dated: February 9, 2016 | | |
/s/ Richard G. Johnson
Richard G. Johnson
Chief Financial Officer |
|
| Dated: February 9, 2016 | | |
/s/ Jack C. Bendheim
Jack C. Bendheim
Chairman, President and Chief Executive Officer |
|
| Dated: February 9, 2016 | | |
/s/ Richard G. Johnson
Richard G. Johnson
Chief Financial Officer |
|
Document and Entity Information - shares |
6 Months Ended | |
---|---|---|
Dec. 31, 2015 |
Feb. 01, 2016 |
|
Entity Registrant Name | PHIBRO ANIMAL HEALTH CORP | |
Entity Central Index Key | 0001069899 | |
Trading Symbol | pahc | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Dec. 31, 2015 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2016 | |
Document Fiscal Period Focus | Q2 | |
Class A common stock | ||
Entity Common Stock, Shares Outstanding | 18,489,757 | |
Class B common stock | ||
Entity Common Stock, Shares Outstanding | 20,899,811 |
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Income Statement [Abstract] | ||||
Net sales | $ 191,773 | $ 188,688 | $ 378,893 | $ 376,146 |
Cost of goods sold | 129,357 | 132,603 | 256,317 | 259,732 |
Gross profit | 62,416 | 56,085 | 122,576 | 116,414 |
Selling, general and administrative expenses | 39,795 | 36,298 | 78,097 | 71,522 |
Operating income | 22,621 | 19,787 | 44,479 | 44,892 |
Interest expense, net | 3,967 | 3,515 | 7,786 | 7,005 |
Foreign currency (gains) losses, net | 2,557 | (1,018) | (2,896) | (2,222) |
Income before income taxes | 16,097 | 17,290 | 39,589 | 40,109 |
Provision (benefit) for income taxes | (14,081) | 3,042 | (9,342) | 6,929 |
Net income | $ 30,178 | $ 14,248 | $ 48,931 | $ 33,180 |
Net income per share: | ||||
basic (in dollars per share) | $ 0.77 | $ 0.37 | $ 1.25 | $ 0.85 |
diluted (in dollars per share) | $ 0.75 | $ 0.36 | $ 1.22 | $ 0.84 |
Weighted average common shares outstanding: | ||||
basic (in shares) | 39,163 | 38,957 | 39,128 | 38,928 |
diluted (in shares) | 39,978 | 39,813 | 39,995 | 39,690 |
Dividends per share (in dollars per share) | $ 0.10 | $ 0.10 | $ 0.20 | $ 0.20 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 30,178 | $ 14,248 | $ 48,931 | $ 33,180 |
Change in fair value of derivative instruments | 1,909 | (294) | (2,994) | (723) |
Foreign currency translation adjustment | 2,014 | (7,358) | (19,715) | (17,338) |
Unrecognized net pension gains (losses) | 508 | 417 | 892 | 702 |
(Provision) benefit for income taxes | (1,371) | 1,157 | 2,315 | 2,706 |
Other comprehensive income (loss) | 3,060 | (6,078) | (19,502) | (14,653) |
Comprehensive income (loss) | $ 33,238 | $ 8,170 | $ 29,429 | $ 18,527 |
CONSOLIDATED BALANCE SHEETS (unaudited) (Parentheticals) - $ / shares |
Dec. 31, 2015 |
Jun. 30, 2015 |
---|---|---|
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 16,000,000 | 16,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Class A common stock | ||
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 18,283,834 | 17,747,793 |
Common stock, shares outstanding | 18,283,834 | 17,747,793 |
Class B common stock | ||
Common stock, shares authorized | 30,000,000 | 30,000,000 |
Common stock, shares issued | 20,959,811 | 21,320,275 |
Common stock, shares outstanding | 20,959,811 | 21,320,275 |
Description of Business |
6 Months Ended |
---|---|
Dec. 31, 2015 | |
Description Of Business [Abstract] | |
Description of Business | 1.
Description of Business
Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (collectively, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, cattle, dairy and aquaculture. The Company is also a manufacturer and marketer of performance products for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” “the Company” and similar expressions refer to Phibro and its subsidiaries.
The unaudited consolidated financial information for the three and six months ended December 31, 2015 and 2014 is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (the “Annual Report”), filed with the Securities and Exchange Commission on September 10, 2015 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of financial position, results of operations and cash flows for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2015 was derived from the audited consolidated financial statements, which include the accounts of Phibro and its consolidated subsidiaries, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.
The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity. Intercompany balances and transactions have been eliminated in the consolidated financial statements.
|
Correction of Prior Year Interim Consolidated Financial Statements |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Changes and Error Corrections [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Correction of Prior Year Interim Consolidated Financial Statements | 2. Correction of Prior Year Interim Consolidated Financial Statements We have revised the consolidated financial statements for the three and six months ended December 31, 2014 to correct errors in accounting for income taxes arising from long-term intercompany investments. We incorrectly recorded the benefits in the provision for income taxes instead of recording the benefits in other comprehensive income. The correcting adjustments increased the provision for income taxes, reduced net income and increased other comprehensive income. We concluded the corrections were not material to the periods.
Consolidated statements of comprehensive income
Consolidated statement of cash flows
|
Summary of Significant Accounting Policies and New Accounting Standards |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies and New Accounting Standards | 3. Summary of Significant Accounting Policies and New Accounting Standards
Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. As of December 31, 2015, there have been no material changes to any of the significant accounting policies contained therein, except for the application of Accounting Standards Update (“ASU”) 2015-17, Income Taxes (Topic 740), during the three months ended December 31, 2015. For further discussion regarding this guidance, see “—New Accounting Standards.” Net Income per Share and Weighted Average Shares
Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.
Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares equivalents resulting from the assumed exercise of stock options and warrants. For the three and six months ended December 31, 2015 and 2014, all common share equivalents were included in the calculation of diluted net income per share.
New Accounting Standards
Financial Accounting Standards Board (“FASB”) ASU 2015-17, Income Taxes (Topic 740), requires entities to classify deferred tax assets and liabilities as noncurrent on the consolidated balance sheet. The guidance is effective for annual periods beginning after December 15, 2016. Early application is permitted, and either retrospective or prospective application is allowed. We have elected early application of this ASU during the quarter ended December 31, 2015 to simplify the presentation of deferred tax assets and liabilities. We applied the guidance prospectively; periods prior to December 31, 2015 were not retrospectively adjusted. The application of this guidance did not have a material impact on our consolidated balance sheet.
ASU 2015-12, Plan Accounting, has multiple parts that may potentially impact our consolidated financial statements. Plan Investment Disclosures (Part II) will eliminate the requirements to disclose individual investments that represent 5 percent or more of net assets available for benefits and the net appreciation or depreciation for investments by general type. The net appreciation or depreciation in investments for the period still will be required to be presented in the aggregate, but will no longer be required to be disaggregated and disclosed by general type. Measurement Date Practical Expedient (Part III) is applicable for fully benefit-responsive investment contracts only, and will allow for the contract value to be the only required method of measurement for these contracts. Under the current guidance these contracts are required to be measured at fair value. The guidance is effective for annual periods beginning after December 15, 2015. Early application is permitted. Retrospective application of the provisions of this guidance will be required. We are evaluating the impact of adoption of this guidance on our consolidated financial statements.
ASU 2015-11, Inventory (Topic 330), requires entities to measure inventory at the lower of cost and net realizable value (“NRV”). NRV is defined as “the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those fiscal years. Early application is permitted. We are evaluating the impact of adoption of this guidance on our consolidated financial statements. ASU 2015-05, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40). The amendments in this Update provide guidance to companies regarding the treatment of cloud computing arrangements and if an arrangement includes a software license. This guidance is effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for both prospective and retrospective transition methods. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30), intends to simplify presentation of debt issuance costs. The provisions of ASU 2015-03 require that debt issuance costs related to a recorded debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the treatment required of debt discounts. The provisions of ASU 2015-03 are effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 will be effective for annual periods ending after December 15, 2016. Earlier adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. Subsequent to June 30, 2015, ASU 2015-14, Revenue from Contracts with Customers—Deferral of the Effective Date, was issued resulting in a one year deferral of the ASU 2014-09 effective date. Thus, ASU 2014-09 is effective for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted for annual periods beginning after December 15, 2016. The guidance should be applied retrospectively to each prior reporting period presented. We are evaluating the impact of adoption of this guidance on our consolidated financial statements.
|
Statements of Operations-Additional Information |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Income Statement Elements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statements of Operations-Additional Information | 4. Statements of Operations—Additional Information
|
Balance Sheets-Additional Information |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheets Additional Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheets-Additional Information | 5. Balance Sheets—Additional Information
Goodwill balances did not change during the six months ended December 31, 2015. We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $4,061 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.
|
Debt |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | 6. Debt Revolving Credit Facility and Term B Loan
We have a revolving credit facility (the “Revolver”) and a term B loan (the “Term B Loan,” and together with the Revolver, the “Credit Facilities”). The Term B Loan has applicable margins equal to 3.00% in the case of LIBOR loans and 2.00% in the case of base rate loans. The LIBOR rate on the Term B Loan is subject to a floor of 1.00%. In January 2016, we amended the agreements governing our Credit Facilities to, among other things, increase the commitment available to us under the Revolver from $100,000 to $200,000. All other material terms and conditions were unchanged.
The Revolver requires, among other things, the maintenance of a maximum consolidated first lien net debt to consolidated EBITDA leverage ratio, calculated on a trailing four quarter basis, and contains an acceleration clause should an event of default (as defined in the agreement governing the Credit Facilities) occur. As of December 31, 2015, we were in compliance with the covenants of the Credit Facilities.
As of December 31, 2015, we had $20,000 in borrowings under the Revolver and had outstanding letters of credit of $14,065, leaving $65,935 available for borrowings and letters of credit under the Revolver. In January 2016 we funded the MVP acquisition with the Revolver. For additional details, see “—Subsequent Event.” We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The tenors of these letters of credit are all one year or less.
The weighted-average interest rates on the Revolver and Term B Loan were 2.88% and 4.00%, respectively, for the six months ended December 31, 2015.
Long-Term Debt
|
Dividends |
6 Months Ended |
---|---|
Dec. 31, 2015 | |
Equity [Abstract] | |
Dividends | 7. Dividends
We intend to pay regular quarterly dividends to holders of our Class A and Class B common stock out of assets legally available for this purpose. We declared and paid quarterly cash dividends totaling $3,917, and $7,827 for the three and six months ended December 31, 2015, to holders of our Class A common stock and Class B common stock. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions. |
Related Party Transactions |
6 Months Ended |
---|---|
Dec. 31, 2015 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 8. Related Party Transactions
Certain relatives of Jack C. Bendheim provided services to us as employees or consultants and received aggregate compensation and benefits of approximately $428 and $1,127 during the three and six months ended December 31, 2015, respectively, and $418 and $1,169 during the three and six months ended December 31, 2014, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.
|
Employee Benefit Plans |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Employee Benefit Plans | 9. Employee Benefit Plans The Company maintains a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to December 31, 2013, who meet certain requirements of age, length of service and hours worked per year. Plan benefits are based upon years of service and average compensation, as defined within the plan.
The following table details the net periodic pension expense:
|
Income Taxes |
6 Months Ended |
---|---|
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 10. Income Taxes
During the three months ended December 31, 2015, we concluded it was more likely than not that the value of domestic deferred tax assets would be realized and it was no longer necessary to maintain a valuation allowance. We have released the domestic valuation allowance, except for amounts that will be released against the utilization of net operating losses during the remainder of the fiscal year. We continue to maintain valuation allowances against deferred tax assets related to certain foreign jurisdictions. We review the realizability of our deferred tax assets on a quarterly basis, or whenever events or changes in circumstances indicate a review is required.
The provision (benefit) for income taxes for the three and six months ended December 31, 2015, included a benefit from the release of a valuation allowance against domestic deferred tax assets of approximately $18,787. Excluding the release of the valuation allowance, the Company’s income tax provisions were comprised primarily of income taxes relating to profitable foreign jurisdictions; income taxes relating to domestic income were substantially offset by the utilization of net operating losses that previously had been offset by the valuation allowance. The provision for income taxes also included benefits from the recognition of certain previously unrecognized tax benefits of $1,637 and $1,218 for the six months ended December 31, 2015 and 2014, respectively.
|
Commitments and Contingencies |
6 Months Ended |
---|---|
Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 11. Commitments and Contingencies Environmental
Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.
While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with, Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements or the cost of compliance.
The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.
The U.S. Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of a facility in Santa Fe Springs, California, operated by our subsidiary Phibro-Tech, Inc. (“Phibro-Tech”). The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that groundwater contamination at its site is due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a nearby property owner has filed a complaint in the Superior Court of the State of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for alleged contamination of groundwater underneath its property, and a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, the Resource Conservation and Recovery Act, as amended, and the common law public nuisance doctrine in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. Due to the ongoing nature of the EPA’s investigation and Phibro-Tech’s dispute with the prior owner’s successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.
Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated our cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be approximately $6,544 and $6,827 at December 31, 2015 and June 30, 2015, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.
Claims and Litigation
PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity. |
Derivatives |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivatives | 12. Derivatives We monitor our exposure to commodity prices, interest rates and foreign currency exchange rates, and use derivatives to manage certain of these risks. These derivatives generally have an expiration/maturity of two years or less and are intended to hedge cash flows related to the purchase of inventory. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). We record the portion of the changes in the value of the derivative, related to a hedged asset or liability (the effective portion), in accumulated other comprehensive income (loss). As the hedged item is sold, we recognize the gain or loss recorded in accumulated other comprehensive income (loss) to the consolidated statements of operations on the same line where the hedged item is charged when released/sold. We immediately recognize in the consolidated statements of operations in the same line as the hedged item, the portion of the changes in fair value of derivatives used as cash flow hedges that is not offset by changes in the expected cash flows related to a recognized asset or liability (the ineffective portion).
We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.
We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “—Fair Value Measurements.”
At December 31, 2015, the following table details the Company’s outstanding derivatives that are designated and effective as cash flow hedges:
The unrecognized gains (losses) at December 31, 2015, are unrealized and will fluctuate based on future exchange rates until the derivative contracts mature. Other comprehensive income (loss) included $1,909 and $(2,994) of unrecognized gains (losses) for the three and six months ended December 31, 2015, respectively. Accumulated other comprehensive income (loss) at December 31, 2015 included $4,536 of unrecognized losses on derivative instruments; we anticipate that $1,196 of the losses will be recognized in earnings within the next twelve months. We realized $1,095 and $1,941 of losses related to contracts that matured during the three and six months ended December 31, 2015, respectively, and recorded the cost as a component of inventory; we anticipate the cost will be recognized in earnings within the next twelve months. We recognize gains (losses) related to these derivative instruments as a component of cost of goods sold at the time the hedged item is sold. We hedge forecasted transactions for periods not exceeding twenty-four months.
|
Fair Value Measurements |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | 13. Fair Value Measurements Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Financial assets and liabilities are measured at fair value using the three-level valuation hierarchy for disclosure of fair value measurements. The determination of the applicable level within the hierarchy of a particular asset or liability depends on the inputs used in the valuation as of the measurement date, notably the extent to which the inputs are market-based (observable) or internally derived (unobservable). Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs based on a company’s own assumptions about market participant assumptions developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:
Level 1— Quoted prices in active markets for identical assets or liabilities. Level 2— Significant observable inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly through corroboration with observable market data. Level 3— Unobservable inputs for which there is little or no market data available, and which are significant to the overall fair value measurement, are employed which require the reporting entity to develop its own assumptions. In assessing the fair value of financial instruments at December 31, 2015 and June 30, 2015, we used a variety of methods and assumptions which were based on estimates of market conditions and risks existing at the time.
Current Assets and Liabilities We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.
Letters of Credit We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The carrying values of these letters of credit are considered to be representative of their fair values because of the nature of the instruments. The tenors of these letters of credit are all one year or less.
Long Term Debt We record the Term B Loan at book value in our consolidated financial statements. We believe the carrying value of the Term B Loan is approximately equal to the fair value, which is based on quoted broker prices that are Level 2 inputs.
Deferred Consideration on Acquisitions We estimated the fair value of the deferred consideration on acquisitions using the income approach, based on the Company’s current sales forecast related to the acquired business.
Derivatives We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation rates.
The table below provides a summary of the changes in the fair value of Level 3 assets:
|
Business Segments |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments | 14. Business Segments The Animal Health segment manufactures and markets products for the poultry, swine, cattle, dairy, aquaculture and ethanol markets. The business includes net sales of medicated feed additives and other related products, nutritional specialty products and vaccines. The Mineral Nutrition segment manufactures and markets trace minerals for the cattle, swine, poultry and pet food markets. The Performance Products segment manufactures and markets a variety of products for use in the personal care, automotive, industrial chemical and chemical catalyst industries.
We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and such costs are referred to as Corporate. We do not allocate such items to the principal segments because they are not used to evaluate their operating results or financial position. Assets include cash and cash equivalents, debt issue costs and certain other assets.
We evaluate performance of our segments based on adjusted EBITDA. We define adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual or non-recurring. We define EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization.
The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.
The Animal Health segment includes all goodwill of the Company. The Animal Health segment includes advances to and investment in an equity method investee of $4,061 and $4,364 as of December 31, 2015 and June 30, 2015, respectively. The Performance Products segment includes an investment in equity method investee of $452 and $361 as of December 31, 2015 and June 30, 2015, respectively. Corporate includes all cash and cash equivalents.
|
Subsequent Event |
6 Months Ended |
---|---|
Dec. 31, 2015 | |
Subsequent Events [Abstract] | |
Subsequent Event | 15. Subsequent Event In January 2016, we purchased the assets of MVP Laboratories, Inc. (“MVP”). MVP is a developer, manufacturer and marketer of livestock vaccines, vaccine adjuvants and other products. We acquired all of the assets used in MVP’s business, including working capital, intellectual property, manufacturing equipment and real property. The purchase price of approximately $46,500 was paid at closing and was funded with the Revolver.
The acquisition will be accounted for as a business combination in accordance with ASC No. 805, “Business Combinations” (“ASC 805”). We are evaluating the allocations of the purchase price to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. Pro forma information giving effect to the acquisition has not been provided because the results are not material to the consolidated financial statements.
|
Summary of Significant Accounting Policies and New Accounting Standards (Policies) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income per Share and Weighted Average Shares | Net Income per Share and Weighted Average Shares
Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.
Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares equivalents resulting from the assumed exercise of stock options and warrants. For the three and six months ended December 31, 2015 and 2014, all common share equivalents were included in the calculation of diluted net income per share.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Standards | New Accounting Standards
Financial Accounting Standards Board (“FASB”) ASU 2015-17, Income Taxes (Topic 740), requires entities to classify deferred tax assets and liabilities as noncurrent on the consolidated balance sheet. The guidance is effective for annual periods beginning after December 15, 2016. Early application is permitted, and either retrospective or prospective application is allowed. We have elected early application of this ASU during the quarter ended December 31, 2015 to simplify the presentation of deferred tax assets and liabilities. We applied the guidance prospectively; periods prior to December 31, 2015 were not retrospectively adjusted. The application of this guidance did not have a material impact on our consolidated balance sheet.
ASU 2015-12, Plan Accounting, has multiple parts that may potentially impact our consolidated financial statements. Plan Investment Disclosures (Part II) will eliminate the requirements to disclose individual investments that represent 5 percent or more of net assets available for benefits and the net appreciation or depreciation for investments by general type. The net appreciation or depreciation in investments for the period still will be required to be presented in the aggregate, but will no longer be required to be disaggregated and disclosed by general type. Measurement Date Practical Expedient (Part III) is applicable for fully benefit-responsive investment contracts only, and will allow for the contract value to be the only required method of measurement for these contracts. Under the current guidance these contracts are required to be measured at fair value. The guidance is effective for annual periods beginning after December 15, 2015. Early application is permitted. Retrospective application of the provisions of this guidance will be required. We are evaluating the impact of adoption of this guidance on our consolidated financial statements.
ASU 2015-11, Inventory (Topic 330), requires entities to measure inventory at the lower of cost and net realizable value (“NRV”). NRV is defined as “the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those fiscal years. Early application is permitted. We are evaluating the impact of adoption of this guidance on our consolidated financial statements.
ASU 2015-05, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40). The amendments in this Update provide guidance to companies regarding the treatment of cloud computing arrangements and if an arrangement includes a software license. This guidance is effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for both prospective and retrospective transition methods. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30), intends to simplify presentation of debt issuance costs. The provisions of ASU 2015-03 require that debt issuance costs related to a recorded debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the treatment required of debt discounts. The provisions of ASU 2015-03 are effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 will be effective for annual periods ending after December 15, 2016. Earlier adoption is permitted. We do not expect adoption of this guidance will have a material effect on our consolidated financial statements.
ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. Subsequent to June 30, 2015, ASU 2015-14, Revenue from Contracts with Customers—Deferral of the Effective Date, was issued resulting in a one year deferral of the ASU 2014-09 effective date. Thus, ASU 2014-09 is effective for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted for annual periods beginning after December 15, 2016. The guidance should be applied retrospectively to each prior reporting period presented. We are evaluating the impact of adoption of this guidance on our consolidated financial statements. |
Correction of Prior Year Interim Consolidated Financial Statements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Changes and Error Corrections [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of error corrections and prior period adjustments |
Consolidated statements of comprehensive income
Consolidated statement of cash flows
|
Summary of Significant Accounting Policies and New Accounting Standards (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of net income per share and weighted average shares |
|
Statements of Operations-Additional Information (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Income Statement Elements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of additional information of statements of operations |
|
Balance Sheets-Additional Information (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheets Additional Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of additional information of balance sheets |
|
Debt (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of long term debt |
|
Employee Benefit Plans (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of net periodic pension expense |
|
Derivatives (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of outstanding derivatives designated and effective as cash flow hedges |
|
Fair Value Measurements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of fair value of derivative instruments based upon pricing models |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of changes in the fair value of Level 3 assets |
|
Business Segments (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of information regarding reportable segments |
|
Correction of Prior Year Interim Consolidated Financial Statements (Details 1) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Consolidated statements of comprehensive income | ||||
Net income (loss) | $ 30,178 | $ 14,248 | $ 48,931 | $ 33,180 |
Other comprehensive income (loss) | 3,060 | (6,078) | (19,502) | (14,653) |
Comprehensive income (loss) | $ 33,238 | 8,170 | $ 29,429 | 18,527 |
As reported | ||||
Consolidated statements of comprehensive income | ||||
Net income (loss) | 15,405 | 35,886 | ||
Other comprehensive income (loss) | (7,235) | (17,359) | ||
Comprehensive income (loss) | 8,170 | 18,527 | ||
Correction | ||||
Consolidated statements of comprehensive income | ||||
Net income (loss) | (1,157) | (2,706) | ||
Other comprehensive income (loss) | $ 1,157 | $ 2,706 | ||
Comprehensive income (loss) |
Correction of Prior Year Interim Consolidated Financial Statements (Details 2) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Consolidated statements of cash flows | ||||
Net income (loss) | $ 30,178 | $ 14,248 | $ 48,931 | $ 33,180 |
Deferred income tax | (2,828) | 176 | ||
Net cash provided (used) by operating activities | $ 5,604 | 25,763 | ||
As reported | ||||
Consolidated statements of cash flows | ||||
Net income (loss) | 15,405 | 35,886 | ||
Deferred income tax | (2,530) | |||
Net cash provided (used) by operating activities | 25,763 | |||
Correction | ||||
Consolidated statements of cash flows | ||||
Net income (loss) | $ (1,157) | (2,706) | ||
Deferred income tax | $ 2,706 | |||
Net cash provided (used) by operating activities |
Summary of Significant Accounting Policies and New Accounting Standards (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Accounting Policies [Abstract] | ||||
Net income (in dollars) | $ 30,178 | $ 14,248 | $ 48,931 | $ 33,180 |
Weighted average number of shares - basic | 39,163 | 38,957 | 39,128 | 38,928 |
Dilutive effect of stock options and warrant | 815 | 856 | 867 | 762 |
Weighted average number of shares - diluted | 39,978 | 39,813 | 39,995 | 39,690 |
Net income per share: | ||||
basic (in dollars per share) | $ 0.77 | $ 0.37 | $ 1.25 | $ 0.85 |
diluted (in dollars per share) | $ 0.75 | $ 0.36 | $ 1.22 | $ 0.84 |
Debt - Summary of long-term debt (Details) - USD ($) $ in Thousands |
Dec. 31, 2015 |
Jun. 30, 2015 |
---|---|---|
Debt Instrument [Line Items] | ||
Capitalized lease obligations | $ 19 | $ 18 |
Long-term debt and capital lease obligations, gross | 285,669 | 287,118 |
Unamortized debt discount | (548) | (600) |
Long-term debt and capital lease obligations, net | 285,121 | 286,518 |
Less: current maturities | (2,814) | (2,809) |
Total | 282,307 | 283,709 |
Term B loan due April 2021 | ||
Debt Instrument [Line Items] | ||
Long-term debt, gross | $ 285,650 | $ 287,100 |
Debt (Detail Textuals) - USD ($) $ in Thousands |
1 Months Ended | 6 Months Ended | |
---|---|---|---|
Jan. 31, 2016 |
Dec. 31, 2015 |
Jun. 30, 2015 |
|
Debt Instrument [Line Items] | |||
Outstanding borrowings | $ 20,000 | $ 3,000 | |
Credit Agreement | Term B Loan | |||
Debt Instrument [Line Items] | |||
Weighted-average interest rates | 4.00% | ||
Credit Agreement | Term B Loan | LIBOR | |||
Debt Instrument [Line Items] | |||
Applicable interest rates | 3.00% | ||
Applicable floor rates | 1.00% | ||
Credit Agreement | Term B Loan | Base Rate | |||
Debt Instrument [Line Items] | |||
Applicable interest rates | 2.00% | ||
Credit Agreement | Revolver | |||
Debt Instrument [Line Items] | |||
Increase in credit facility | $ 100,000 | ||
Outstanding borrowings | 20,000 | ||
Outstanding letters of credit | 14,065 | ||
Available borrowings under credit lines | $ 65,935 | ||
Weighted-average interest rates | 2.88% | ||
Credit Agreement | Revolver | Subsequent Event | |||
Debt Instrument [Line Items] | |||
Increase in credit facility | $ 200,000 |
Dividends (Detail Textuals) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |
---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Dividends [Line Items] | |||
Cash dividends paid | $ 3,917 | $ 7,827 | $ 7,791 |
Class A common stock | |||
Dividends [Line Items] | |||
Cash dividends paid | 3,917 | 7,827 | |
Class B common stock | |||
Dividends [Line Items] | |||
Cash dividends paid | $ 3,917 | $ 7,827 |
Related Party Transactions (Detail Textuals) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Relatives of Jack C. Bendheim | Compensation And Benefit For Services | ||||
Related Party Transaction [Line Items] | ||||
Aggregate compensation and benefits | $ 428 | $ 418 | $ 1,127 | $ 1,169 |
Employee Benefit Plans - Net periodic pension expense (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Compensation and Retirement Disclosure [Abstract] | ||||
Service cost - benefits earned during the period | $ 751 | $ 656 | $ 1,470 | $ 1,477 |
Interest cost on benefit obligation | 757 | 574 | 1,446 | 1,309 |
Expected return on plan assets | (846) | (648) | (1,588) | (1,414) |
Amortization of net actuarial (gain) loss and prior service costs | 508 | 417 | 892 | 702 |
Net periodic pension expense | $ 1,170 | $ 999 | $ 2,220 | $ 2,074 |
Income Taxes (Detail Textuals) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |
---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Income Tax Disclosure [Abstract] | |||
Deferred income taxes valuation allowance | $ (18,787) | $ (18,787) | |
Unrecognized tax benefits | $ 1,637 | $ 1,637 | $ 1,218 |
Commitments and Contingencies (Detail Textuals) $ in Thousands |
6 Months Ended | 12 Months Ended |
---|---|---|
Dec. 31, 2015
USD ($)
Party
|
Jun. 30, 2015
USD ($)
|
|
Commitments And Contingencies [Line Items] | ||
Number of potentially responsible parties | Party | 140 | |
Current and long-term liabilities | ||
Commitments And Contingencies [Line Items] | ||
Accrual for environmental loss contingencies payments | $ | $ 6,544 | $ 6,827 |
Derivatives (Details) - Options - Cash flow hedges - USD ($) $ in Thousands |
Dec. 31, 2015 |
Jun. 30, 2015 |
---|---|---|
Brazilian Real calls | ||
Derivative [Line Items] | ||
Notional amount | $ 156,000 | |
Fair value | 675 | $ 493 |
Brazilian Real puts | ||
Derivative [Line Items] | ||
Notional amount | 156,000 | |
Fair value | $ (5,211) | $ (2,035) |
Derivatives (Detail Textuals) - Options - Cash flow hedges $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2015
USD ($)
|
|
Derivative [Line Items] | ||
Other comprehensive income (loss), unrealized gains (losses) on derivatives | $ 1,909 | $ (2,994) |
Accumulated other comprehensive income (loss) of unrecognized gains (losses) on derivative instruments | 4,536 | 4,536 |
Unrecognized gains (losses) on derivative instruments recorded in earnings within the next twelve months | (1,196) | |
Realized losses on derivative instruments | $ (1,095) | $ (1,941) |
Fair Value Measurements (Details) - Fair value - USD ($) $ in Thousands |
Dec. 31, 2015 |
Jun. 30, 2015 |
---|---|---|
Level 1 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Derivatives | ||
Deferred consideration on acquisition | ||
Level 2 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Derivatives | $ (4,536) | $ (1,542) |
Deferred consideration on acquisition | ||
Level 3 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Derivatives | ||
Deferred consideration on acquisition | $ 5,958 | $ 5,465 |
Fair Value Measurements (Details 1) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Dec. 31, 2015 |
Dec. 31, 2015 |
|
Business Combination, Contingent Consideration [Roll Forward] | ||
Acquisition related accrued interest | $ 344 | $ 689 |
Fair value | Level 3 | ||
Business Combination, Contingent Consideration [Roll Forward] | ||
Balance, June 30, 2015 | 5,465 | |
Acquisition related accrued interest | 689 | |
Payment and other | (196) | |
Balance, December 31, 2015 | $ 5,958 | $ 5,958 |
Business Segments (Detail Textuals) - USD ($) $ in Thousands |
Dec. 31, 2015 |
Jun. 30, 2015 |
---|---|---|
Animal Health | ||
Segment Reporting Information [Line Items] | ||
Equity method investments | $ 4,061 | $ 4,364 |
Performance Products | ||
Segment Reporting Information [Line Items] | ||
Equity method investments | $ 452 | $ 361 |
Subsequent Event (Detail Textuals) $ in Thousands |
Jan. 31, 2016
USD ($)
|
---|---|
Subsequent Event | MVP Laboratories, Inc | |
Subsequent Event [Line Items] | |
Purchase price of assets acquired | $ 46,500 |
2/
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MC "APY 'S&>$^>6V-2L6' "78M5N,;MW1XW>O#!<-1KH A##.4WEV834<1\I1$;89D7' Y93:[$&4V11,V
M(8.+488XRNE=BMF(G-U^YT@V\:6[*&4V2_F-(;8Q.1/ Z:F:85T$,4P89'"!
M"C90Z=6W@A"5GJ0IO7,ZNC1)^ 1'+E,!,973>SG8M)S)F,8&4DV9@^ 2%1!1
M.;U* ;-2TA,(J7@ZZ6VY2 6$5$[OQ6##<@:2_G[('!F/)C >7*@"I]>H_7D,
M-BUG,?L'=N9*P33(:AXRBPCB"'?*=^Y,VNJ%OO57?F-#,;9:=\ID"Q],
MF7MSRKPV2K7M^MNXKW\\=XV-3A\NQ\CK67;Y%U!+ P04 " /A$E(V,9'
MLCP" "*!P &0 'AL+W=O DJ:%5XY$3RGF?UZ L.'H^,X4>&NJ6NJ
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MWF.!:!((K4"T%/"\M&PO=V]R:W-H965T3_;7MOO=G:X?H1UTU_?/N/ R7ISCN7\^V+OK/[<4V[C^GMJN+
MP1UV;W%_Z6QQG(KJ*N:,J;@NRF9WV$_GOG:'??L^5&5COW91_U[71?=?9JOV
M^KR#W>W$M_+M/(PGXL,^OM<=R]HV?=DV46=/S[LO\)1S,T:FQ-^EO?;H>S3"
MO[3M]_'@S^/SCHT,MK*OP]A$X3X^;&ZK:FS)]?SOTNC//L="_/W6^N_3(\D]$KO^20A^
M@U S!,?UZG&]N-7/AU\$KM<^HIX',4>:>1")T)Q*Y5XJY;"!108L$K,8OY=D
M9I&H%P"9A#!S+/=CP-+T,4T2T"28)B5I$MQ-(B6G:;R83+79<&U40*,0C6(D
MC?)H#-,D#$YQH;A^S*(#%HU9@&31J![L6$-ND&5P&$/-AVBAQWMF3FCA(^KA<:".=D*@1LF#L0ZA.P/]6&
M=0FA0 $;5)&L&7AR-$#>B3Q(L0W.@E"A@!VJ:(<"MJ,"SA6-X\4$4UMF8"A1
MP!95M$4!^S%A,J57IQ>3B42K:YTGU"A@CVK:H^")U#UDQ J0GP,AMA"%,@5L
M4TW;%+ GW6:2D>"Y%Q,XM8X3VA2P3NFG:P;&FZA F*/*:70-HRDF2PSJG6'*8YW]9))^+%*E(O@*4WP.*&;!-@&(%J+X'
ME)\Z*%> [7K,^S1FRM$QI]Q66?:I#+LYV8&?X9F;L]"6'-'Y2XHGVB$Z\*SL
MKJ*D]T]A<21T+ICWWC;I[TB.PV'^UY<'U_P#4$L#!!0 ( ^$24@P/I6.
M!DD $A$ 0 4 >&PO